KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Net Margin (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Net Margin for 10 consecutive years, with 9.89% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 1658.0% year-over-year to 9.89%, compared with a TTM value of 8.83% through Dec 2025, up 2548.0%, and an annual FY2025 reading of 8.11%, up 2000.0% over the prior year.
  • Net Margin was 9.89% for Q4 2025 at Teva Pharmaceutical Industries, down from 14.33% in the prior quarter.
  • Across five years, Net Margin topped out at 14.33% in Q3 2025 and bottomed at 54.79% in Q4 2022.
  • Average Net Margin over 5 years is 17.89%, with a median of 18.53% recorded in 2024.
  • Peak annual rise in Net Margin hit 9188bps in 2021, while the deepest fall reached -3061bps in 2021.
  • Year by year, Net Margin stood at 27.24% in 2021, then crashed by -101bps to 54.79% in 2022, then skyrocketed by 92bps to 4.22% in 2023, then crashed by -59bps to 6.69% in 2024, then skyrocketed by 248bps to 9.89% in 2025.
  • Business Quant data shows Net Margin for TEVA at 9.89% in Q4 2025, 14.33% in Q3 2025, and 4.86% in Q2 2025.